Immunome (IMNM) Return on Capital Employed (2023 - 2025)
Historic Return on Capital Employed for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to 0.88%.
- Immunome's Return on Capital Employed rose 4600.0% to 0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88%, marking a year-over-year increase of 4600.0%. This contributed to the annual value of 2.18% for FY2024, which is N/A changed from last year.
- Latest data reveals that Immunome reported Return on Capital Employed of 0.88% as of Q3 2025, which was up 4600.0% from 0.76% recorded in Q2 2025.
- Over the past 5 years, Immunome's Return on Capital Employed peaked at 0.76% during Q2 2025, and registered a low of 1.57% during Q4 2024.
- In the last 3 years, Immunome's Return on Capital Employed had a median value of 1.06% in 2024 and averaged 1.08%.
- Per our database at Business Quant, Immunome's Return on Capital Employed tumbled by -4700bps in 2024 and then soared by 4600bps in 2025.
- Quarter analysis of 3 years shows Immunome's Return on Capital Employed stood at 1.11% in 2023, then tumbled by -42bps to 1.57% in 2024, then skyrocketed by 44bps to 0.88% in 2025.
- Its last three reported values are 0.88% in Q3 2025, 0.76% for Q2 2025, and 0.84% during Q1 2025.